Recently, Baoshan District, Shanghai, signed a contract with Lanque Biotechnology(Rnacure) to build an mRNA clinical drug R&D and GMP production base . Lanque Biology will plan and build a 5000 square meter R&D center and a 10,000 square meter GMP production base in Songnan Town and Luodian Town respectively, forming a spatial layout of “Southern R&D and North Production”. At that time, more than 10 preclinical and clinical projects will be developed at the same time, including infectious disease vaccines, tumor immunotherapy, protein replacement therapy, and gene editing for rare diseases, and will have the preparation and production capacity of 50 million doses of mRNA drugs for clinical trials. The integrated mRNA drug development program from conception to implementation has comprehensively improved R&D and production capabilities in terms of quality, speed, scale and cost, and fully released the huge potential of mRNA platform technology.
Lanque Biopharmaceutical (Shanghai) Co., Ltd. was established in April 2019. It is a new drug research and development company focusing on mRNA drug innovation research. It has developed one-step mRNA drug development from mRNA synthesis and early discovery of new targets to rapidly expanding product lines. The platform already has the world’s leading mRNA raw materials and drug production technology. The core team of the company is composed of high-level scientific researchers from well-known overseas universities and research institutions such as Harvard University, Yale University and Swedish Caroline College, and has accumulated more than ten years of research experience in related fields. Lanque Biopharmaceutical (Shanghai) Co., Ltd. is committed to building a full-chain platform of mRNA from R&D to production, accelerating the application of mRNA in multiple therapeutic fields.